Patient P-02094
Therapy response
Improving
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
94%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 47 NP-02 recommended — Dietary Support Protocol NP-02
- Day 48 Patient accepted — Started NP-02 in the companion
- Day 58 GI symptom burden −18% vs expected — Dietary Support Protocol NP-02
- Day 64 Tolerance state changed — Unstable → Improving
- Day 71 SC-12 recommended — Supportive Compound SC-12
- Day 72 Patient accepted — Started SC-12 in the companion
- Day 77 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 78 No meaningful change — Supportive Compound SC-12
- Day 80 GI-04 recommended — GI Support Protocol GI-04
- Day 81 Patient declined — Not now
- Day 87 ME-01 recommended — Monitoring Escalation ME-01
- Day 88 Patient accepted — Started ME-01 in the companion
- Day 91 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 77.
Primary contributors, last 14 days
- Treatment adherence+10
- Nutritional resilience+9
- Toxicity-7
- GI instability-5
What helped?
- Dietary Support Protocol NP-02Day 47Result: symptom burden −18%
- Supportive Compound SC-12Day 71Result: no meaningful change
- GI Support Protocol GI-04Day 80Declined by patient
- Monitoring Escalation ME-01Day 87Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 89% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 40/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 66 and rising
- WearableSleep 5.6 h, below personal baseline
- Inflammatory signalling ↓40
- BloodInflammatory load index 68
- WearableHRV 26 ms, trending down
- Autonomic recovery ↑40
- Wearable574 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 55
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.3 · butyrate capacity 40/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 18 ms
- Sleep
- 6.0 h
- Steps
- 968
- Resting HR
- 69 bpm
Daily log: GI score 66, nutritional resilience 36, adherence 53.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02018 | 42% | S01 | GI-04 | improved | 46 |
| P-02409 | 34% | S01 | SC-12 | no change | 54 |
| P-02410 | 33% | S01 | GI-04 | improved | 55 |
| P-02054 | 31% | S01 | CR-01 | improved | 57 |
| P-02307 | 21% | S01 | — | — | 55 |
| P-02598 | 21% | S01 | — | — | 53 |
| P-02550 | 20% | S01 | — | — | 70 |
| P-02041 | 19% | S01 | — | — | 27 |
| P-02276 | 19% | S01 | — | — | 57 |
| P-02437 | 19% | S01 | — | — | 64 |
| P-02568 | 19% | S01 | — | — | 51 |
| P-02297 | 40% | S02 | NP-02 | improved | 49 |